Quibim has completed a series A financing round worth $50 million (€47.9 million).
With operations in Spain, the U.K., and the U.S., the company said the investment will allow it to establish a stronger U.S. presence, building on its success in Europe, through strategic collaborations with hospitals and pharmaceutical companies.
Quibim has been developing human digital twin technology at the organ and lesion level, as well as AI models designed to extract actionable insights from MRI, CT, and PET scans. However, as the volume of whole-body scans and related imaging data continues to grow, in the coming years the main goal is to analyze the entire body, the company noted.
Quibim's QP-Prostate, QP-Brain, QP-Liver, and QP-Insights are cleared for use in the European Union and the U.K. through the CE and UKCA marks, and QP-Insights is already in use as part of the European Cancer Imaging Initiative to support Europe’s Beating Cancer Plan.
Asabys and Buenavista Equity Partners led this round of financing. UI Investissements and GoHub Ventures were noted as new investors. Others included Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, and Leadwind, as well as individual investors.
